Geoff Mcdonough - 08 Jun 2021 Form 4 Insider Report for Surface Oncology, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 08 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2021, 16:30:16 UTC
Next SEC filing: 25 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Jessica Fees, as Attorney-in-Fact

Key filing fact

Geoff Mcdonough filed Form 4 for Surface Oncology, Inc. on 10 Jun 2021.

Key facts

This page summarizes Geoff Mcdonough's Form 4 filing for Surface Oncology, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2021, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SURF transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,700
Change %
Price: $0.000000
Shares after: 17,700
Date: 08 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,700
Exercise price: $7.69
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Options shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.